是什么决定了疫苗的价值？
What Drives the Value of a Vaccine?
作者信息
Hausdorff William P, Scheele Suzanne, Giersing Birgitte K
机构信息
Center for Vaccine Innovation and Access, PATH, 455 Massachusetts Ave NW, Washington, DC 20001, USA.
Faculty of Medicine, Université Libre de Bruxelles, 1050 Brussels, Belgium.
出版信息
Vaccines (Basel). 2022 Feb 12;10(2):282. doi: 10.3390/vaccines10020282.
Abstract
The development and licensure of a safe and highly efficacious vaccine has been a priority in international public health circles for decades and would represent a great scientific achievement. Nonetheless, in the context of increasingly crowded and costly childhood immunization programs, and with a myriad of other new and improved vaccines currently or soon on the market, there is no guarantee that even a highly effective vaccine would become a priority for adoption and introduction by the low- and middle-income countries that could benefit from it the most. We discuss here some of the major determinants and questions regarding the introduction of vaccines and the importance of developing a succinct, compelling public health value proposition.
摘要
几十年来，研发和批准一种安全且高效的疫苗一直是国际公共卫生界的首要任务，这将是一项重大的科学成就。然而，在儿童免疫规划日益拥挤且成本高昂的背景下，以及目前或即将上市的大量其他新型和改良疫苗的情况下，即使是一种高效疫苗，也不能保证会成为最能从中受益的低收入和中等收入国家采用和引入的优先选择。我们在此讨论一些关于疫苗引入的主要决定因素和问题，以及制定一个简洁、有说服力的公共卫生价值主张的重要性。
相似文献
1
What Drives the Value of a Vaccine?是什么决定了疫苗的价值？
Vaccines (Basel). 2022 Feb 12;10(2):282. doi: 10.3390/vaccines10020282.
2
Reassessing potential economic value and health impact of effective vaccines.重新评估有效疫苗的潜在经济价值和健康影响。
Bull World Health Organ. 2024 Jan 1;102(1):65-74. doi: 10.2471/BLT.23.290163. Epub 2023 Dec 11.
3
Challenges and opportunities in developing a Shigella-containing combination vaccine for children in low- and middle-income countries: Report of an expert convening.为低收入和中等收入国家儿童开发含志贺氏菌联合疫苗的挑战与机遇：专家会议报告
Vaccine. 2023 Apr 17;41(16):2634-2644. doi: 10.1016/j.vaccine.2023.03.003. Epub 2023 Mar 15.
4
Exploring vaccine priorities and preferences: Results from a mixed-methods study in low- and middle-income settings.探索疫苗接种优先级和偏好：来自低收入和中等收入地区的一项混合方法研究结果
Vaccine X. 2023 Aug 9;15:100368. doi: 10.1016/j.jvacx.2023.100368. eCollection 2023 Dec.
5
Could a vaccine impact long-term health outcomes?: Summary report of an expert meeting to inform a vaccine public health value proposition, March 24 and 29, 2021.疫苗会影响长期健康结果吗？：2021年3月24日和29日关于为疫苗公共卫生价值主张提供信息的专家会议总结报告
Vaccine X. 2022 Sep 21;12:100218. doi: 10.1016/j.jvacx.2022.100218. eCollection 2022 Dec.
6
WHO consultation on ETEC and Shigella burden of disease, Geneva, 6-7th April 2017: Meeting report.世界卫生组织关于肠产毒性大肠杆菌和志贺氏菌疾病负担的磋商会议报告，日内瓦，2017 年 4 月 6-7 日。
Vaccine. 2019 Nov 28;37(50):7381-7390. doi: 10.1016/j.vaccine.2017.10.011. Epub 2018 Jan 17.
7
Data and product needs for influenza immunization programs in low- and middle-income countries: Rationale and main conclusions of the WHO preferred product characteristics for next-generation influenza vaccines.低收入和中等收入国家流感免疫规划的数据和产品需求：世卫组织下一代流感疫苗首选产品特性的基本原理和主要结论
Vaccine. 2017 Oct 13;35(43):5734-5737. doi: 10.1016/j.vaccine.2017.08.088. Epub 2017 Sep 20.
8
The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshops.2022 年志贺氏菌和肠产毒性大肠杆菌疫苗（VASE）会议：分组研讨会总结。
Vaccine. 2024 Mar 7;42(7):1445-1453. doi: 10.1016/j.vaccine.2023.11.045. Epub 2023 Nov 30.
9
The Vaccines Pipeline.疫苗研发进程
Vaccines (Basel). 2022 Aug 24;10(9):1376. doi: 10.3390/vaccines10091376.
10
Vaccine value profile for Shigella.志贺菌疫苗价值简介。
Vaccine. 2023 Nov 3;41 Suppl 2:S76-S94. doi: 10.1016/j.vaccine.2022.12.037. Epub 2023 Oct 10.
引用本文的文献
1
Prevalence of Shigella species and antimicrobial resistance patterns in Africa: systematic review and meta-analysis.非洲志贺菌属物种的流行情况和抗生素耐药模式：系统评价和荟萃分析。
BMC Infect Dis. 2024 Oct 29;24(1):1217. doi: 10.1186/s12879-024-09945-2.
2
Reassessing potential economic value and health impact of effective vaccines.重新评估有效疫苗的潜在经济价值和健康影响。
Bull World Health Organ. 2024 Jan 1;102(1):65-74. doi: 10.2471/BLT.23.290163. Epub 2023 Dec 11.
3
Clinical and regulatory development strategies for Shigella vaccines intended for children younger than 5 years in low-income and middle-income countries.用于 5 岁以下儿童的志贺氏菌疫苗的临床和监管开发策略在低收入和中等收入国家。
Lancet Glob Health. 2023 Nov;11(11):e1819-e1826. doi: 10.1016/S2214-109X(23)00421-7.
4
Exploring vaccine priorities and preferences: Results from a mixed-methods study in low- and middle-income settings.探索疫苗接种优先级和偏好：来自低收入和中等收入地区的一项混合方法研究结果
Vaccine X. 2023 Aug 9;15:100368. doi: 10.1016/j.jvacx.2023.100368. eCollection 2023 Dec.
5
Potential impact and cost-effectiveness of Shigella vaccination in 102 low-income and middle-income countries in children aged 5 years or younger: a modelling study.在 102 个中低收入国家，5 岁及以下儿童接种志贺氏菌疫苗的潜在影响和成本效益：一项建模研究。
Lancet Glob Health. 2023 Jun;11(6):e880-e891. doi: 10.1016/S2214-109X(23)00192-4.
6
Frontiers in Vaccine Development.疫苗开发前沿
Vaccines (Basel). 2022 Sep 15;10(9):1536. doi: 10.3390/vaccines10091536.
7
The Vaccines Pipeline.疫苗研发进程
Vaccines (Basel). 2022 Aug 24;10(9):1376. doi: 10.3390/vaccines10091376.
8
Healthcare provider perspectives on delivering next generation rotavirus vaccines in five low-to-middle-income countries.医疗服务提供者在五个中低收入国家推广下一代轮状病毒疫苗的观点。
PLoS One. 2022 Jun 23;17(6):e0270369. doi: 10.1371/journal.pone.0270369. eCollection 2022.
9
Incidence of Asymptomatic Infection and Association with the Composite Index of Anthropometric Failure among Children Aged 1-24 Months in Low-Resource Settings.资源匮乏地区1至24个月儿童无症状感染的发生率及其与人体测量失败综合指数的关联
Life (Basel). 2022 Apr 19;12(5):607. doi: 10.3390/life12050607.
本文引用的文献
1
The Full Value of Vaccine Assessments (FVVA): a framework for assessing and communicating the value of vaccines for investment and introduction decision-making.疫苗评估的全部价值（FVVA）：评估和沟通疫苗投资和引入决策价值的框架。
BMC Med. 2023 Jul 4;21(1):229. doi: 10.1186/s12916-023-02929-0.
2
Could a vaccine impact long-term health outcomes?: Summary report of an expert meeting to inform a vaccine public health value proposition, March 24 and 29, 2021.疫苗会影响长期健康结果吗？：2021年3月24日和29日关于为疫苗公共卫生价值主张提供信息的专家会议总结报告
Vaccine X. 2022 Sep 21;12:100218. doi: 10.1016/j.jvacx.2022.100218. eCollection 2022 Dec.
3
From Concept to Clinical Product: A Brief History of the Novel Invaplex Vaccine's Refinement and Evolution.从概念到临床产品：新型Invaplex疫苗的优化与演进简史。
Vaccines (Basel). 2022 Apr 1;10(4):548. doi: 10.3390/vaccines10040548.
4
Potential impact and cost-effectiveness of injectable next-generation rotavirus vaccines in 137 LMICs: a modelling study.137 个中低收入国家中可注射的新一代轮状病毒疫苗的潜在影响和成本效益：一项建模研究。
Hum Vaccin Immunother. 2022 Dec 31;18(1):2040329. doi: 10.1080/21645515.2022.2040329. Epub 2022 Mar 3.
5
Does Anybody Want an Injectable Rotavirus Vaccine, and Why? Understanding the Public Health Value Proposition of Next-Generation Rotavirus Vaccines.有人想要注射用轮状病毒疫苗吗？为什么？理解下一代轮状病毒疫苗的公共卫生价值主张。
Vaccines (Basel). 2022 Jan 20;10(2):149. doi: 10.3390/vaccines10020149.
6
National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study.国家利益相关者对下一代轮状病毒疫苗的偏好：来自六个国家的研究结果。
Vaccine. 2022 Jan 21;40(2):370-379. doi: 10.1016/j.vaccine.2021.11.009. Epub 2021 Dec 2.
7
World Health Organization Expert Working Group: Recommendations for assessing morbidity associated with enteric pathogens.世界卫生组织专家工作组：评估肠道病原体相关发病率的建议。
Vaccine. 2021 Dec 20;39(52):7521-7525. doi: 10.1016/j.vaccine.2021.11.033. Epub 2021 Nov 24.
8
Efficacy, safety, and immunogenicity of the 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults.1790GAHB颗粒巨噬细胞甘露糖结合凝集素候选疫苗的疗效、安全性及免疫原性：一项针对成人的2b期随机、安慰剂对照激发试验的结果
EClinicalMedicine. 2021 Aug 13;39:101076. doi: 10.1016/j.eclinm.2021.101076. eCollection 2021 Sep.
9
The CAPACITI Decision-Support Tool for National Immunization Programs.国家免疫规划决策支持工具 CAPACITI。
Value Health. 2021 Aug;24(8):1150-1157. doi: 10.1016/j.jval.2021.04.1273. Epub 2021 Jun 18.
10
Global diarrhoea-associated mortality estimates and models in children: Recommendations for dataset and study selection.全球儿童腹泻相关死亡率估计和模型：数据集和研究选择建议。
Vaccine. 2021 Jul 22;39(32):4391-4398. doi: 10.1016/j.vaccine.2021.05.086. Epub 2021 Jun 13.
Zotero 插件